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Abstract
β-cells release hexameric Zn2+-insulin into the extracellular space, but monomeric Zn2+-free
insulin appears to be the only biologically active form. The mechanisms implicated in disso-
ciation of the hexamer remain unclear, but they seem to be Zn2+ concentration-dependent.
In this study, we investigate the influence of albumin binding to Zn2+ on Zn2+-insulin dissoci-
ation into Zn2+-free insulin and its physiological, methodological and therapeutic relevance.
Glucose and K+-induced insulin release were analyzed in isolated mouse islets by static
incubation and perifusion experiments in the presence and absence of albumin and Zn2+
chelators. Insulin tolerance tests were performed in rats using different insulin solutions with
and without Zn2+ and/or albumin. Albumin-free buffer does not alter quantification by RIA of
Zn2+-free insulin but strongly affects RIA measurements of Zn2+-insulin. In contrast, accu-
rate determination of Zn2+-insulin was obtained only when bovine serum albumin or Zn2+
chelators were present in the assay buffer solution. Albumin and Zn2+ chelators do not mod-
ify insulin release but do affect insulin determination. Preincubation with albumin or Zn2+
chelators promotes the conversion of “slow” Zn2+-insulin into “fast” insulin. Consequently,
insulin diffusion from large islets is ameliorated in the presence of Zn2+ chelators. These
observations support the notion that the Zn2+-binding properties of albumin improve the dis-
sociation of Zn2+-insulin into subunits after exocytosis, which may be useful in insulin deter-
mination, insulin pharmacokinetic assays and islet transplantation.
Introduction
The insulin concentration in blood is approximately 1 ng/ml, and the predominant form is
monomeric [1]. However, the insulin molecule associates into hexamers at higher insulin con-
centrations, and this feature is favored by acid or neutral pH and Zn2+ [2–4]. In β-cells, insulin
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is stored in the secretory granules as hexamers coordinated with two Zn2+ ions per hexamer
[3]. In response to a stimulus, such as a rise of blood glucose or an increase in extracellular K+
concentration, β-cells release the hexameric Zn2+-insulin to the extracellular space [5]. How-
ever, in vivo experiments show that insulin is available as monomer within a few seconds of
entering the portal vein [6]. In addition, it is generally accepted that the biologically active
form of insulin is the monomer and not the hexamer. The reasons for this are i) the monomer
is the predominant form in the bloodstream, ii) the majority of the receptor binding region is
located at the dimer-forming surface [7,8] and iii) the insulin hexamer seems to be ineffective
at activating the insulin receptor [9,10]. Thus, the physiological process of hexamer dissocia-
tion is a very important but poorly understood step in the regulation of insulin availability and
glucose homeostasis by the organism.
It is established that at pH 7.3, Zn2+ coordination prevents hexamer dissociation into
monomers. Thus, Zn2+ dilution and pH changes have been proposed as mechanisms to facili-
tate Zn2+-insulin hexamer disintegration [11]. However, micromolar Zn2+ concentrations,
lower than that found in serum (15–25 μmol/l) [12,13], can affect free insulin concentrations,
thereby improving the self-association of monomers to form Zn2+-insulin hexamers [5]. Fur-
thermore, Zn2+ concentrations in the secretory granule have been estimated to be approxi-
mately 20 mmol/l [14]. Consequently, high concentrations of Zn2+ ions are likely to be
produced locally in the interstitial space and in the capillaries of the pancreatic-islet core. In
this environment of high Zn2+ concentration, it may be possible that a major fraction of Zn2+-
insulin does not dissociate per se into monomers after exocytosis. It may be thus conceivable
that Zn2+ chelation could facilitate hexamer dissociation. We postulate that blood albumin
could play a significant role in this respect. Albumin binds to Zn2+ with high affinity [15] and
is the main transport protein of Zn2+ in blood [16]. Additionally, the islet is a notably well-vas-
cularized tissue, and albumin arrives close to the places of insulin exocytosis. While any intra-
cellular space in the islet may be considered virtual, the intravascular space represents 20% of
islet architecture. Furthermore, it is known that in certain cases, albumin penetrates into the
extracellular space between the endocrine cells [17]. Finally, while electrical activity and intra-
cellular calcium measurements in β-cells can be performed in free albumin solutions [18–20],
secretion experiments require the presence of albumin in the medium [19,20]. Thus, albumin
seems to affect insulin secretion in steps downstream of the calcium-dependent exocytotic
process. The fact reported in this study, that both albumin and Zn2+ chelation allow insulin to
be measured by radioimmunoassay, leads us to hypothesize a physiological role for this plasma
protein in hexamer dissociation and the subsequent biological activity of the hormone.
In the present study, we analyze the effect of the Zn2+ binding properties of serum albumin




All of the insulin release experiments were carried out at 37˚C with fresh modified Krebs-
Ringer bicarbonate (KRB) buffer containing (in mmol/l): 120 NaCl, 5 KCl, 25 NaHCO3, 1.1
MgCl2, 2.5 CaCl2. For islet isolation and insulin dilution KRB buffer containing (in mmol/l):
115 NaCl, 5 KCl, 10 NaHCO3, 1.1 MgCl2, 1.2 NaH2PO4 and 25 acid Hepes was used. All of the
previously mentioned solutions were prewarmed at 37˚C and continuously gassed with a mix-
ture of O2 (95%) and CO2 (5%) for a final pH of 7.4. The medium used for islet culture was
RPMI 1640 supplemented with 10% fetal calf serum, 100 IU/ml penicillin, 0.1 mg/ml strepto-
mycin, and 11 mmol/l glucose. For insulin tolerance test (ITT), 4 μmol/l insulin stocks, of
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Zn2+-free or Zn2+-insulin, with or without 3% bovine serum albumin (BSA) were prepared
and kept at 37˚C for 20 min before injection. Human recombinant free insulin (Humulin Reg-
ular) and Zn2+-insulin (Ultralent Humulin) were from Lilly (Indianapolis, IN, USA). BSA,
2-carboxy-2’-hydroxy-5’sulfoformazyl-benzene (Zincon) and 2,2’:6’,2”-terpypridine (Terpy)
were from (Sigma, St. Louis, MO, USA).
Islet isolation
Islets from adult (8–10 weeks old) male Swiss albino mice (Charles River, France) were isolated
as previously described [21]. Briefly, after pancreatic digestion with collagenase (Collagenase
A; Boehringer Mannheim, Germany) in a stationary bath at 37˚C, islets were separated by cen-
trifugation and hand-picked under a stereomicroscope. Once isolated, the islets were then cen-
trifuged and resuspended in culture medium, kept at 37˚C in a humidified atmosphere of 95%
O2, 5% CO2 and used between 2–3 h of culture. Mice were sacrificed by cervical dislocation.
Insulin tolerance test (ITT)
Male Wistar rats (8–9 weeks old) (Charles River, France) were allowed free access to standard
food and water ad libitum until experiments were performed. For experimental procedures
rats were fasted for 5–6 h. Anesthesia was performed by intraperitoneal injection of sodium
pentobarbital (60 mg/kg body weight) and the experiments were carried out after loss of cor-
neal and pedal reflexes. The previously mentioned insulin stocks (4 μmol/l) were subcutane-
ously injected at 0.5 ml/kg body weight into the rats’ hind back, and blood samples were
collected from the tail at 0, 10, 20, 30, 40 and 60 min for measurement of serum glucose and
insulin. Rats were sacrificed by terminal anesthesia with sodium pentobarbital.
This study was conducted in strict accordance with the recommendations in the Guide for
the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was
approved by the Committee on the Ethics of Animal Experiments of the Andalusian Center of
Molecular Biology and Regenerative Medicine (Protocol number: 06-10-14-138). All surgery
was performed under sodium pentobarbital anesthesia, and all efforts were made to minimize
suffering.
Insulin release experiments
Insulin measurements were performed as previously described [20]. For static incubation,
islets were placed in groups of 3, for 30 min at 37˚C, in 1 ml of KRB buffer with or without
2.5% BSA plus the different glucose concentrations (2.8 and 22.2 mmol/l). For islet perifusion
experiments, batches of 10 large-size islets (308 ± 49 μm in diameter) or 40 small-size islets
(56 ± 11 μm in diameter) were placed in a 100 μl chamber and perifused with KRB buffer with
or without 1 mmol/l Zincon plus 0.1% BSA and 2.8 mmol/l glucose at a flow rate of 1 ml/min.
The pancreatic islets were first perifused in the presence of 2.8 mmol/l glucose for 30 min to
reach a state of insulin release. Throughout the perfusion, effluent was continuously collected
at 30-second intervals. The dead time was 2 min and has been corrected for in the figures.
Both static incubation and perifused samples were kept at -20˚C until insulin determination.
Insulin determination
Insulin was assayed by radioimmunoassay (RIA) using a kit from DPC (Los Angeles, CA,
USA). The RIA included polypropylene tubes coated with antibodies to human recombinant
insulin and was carried out following these steps: i) addition of samples to the antibody-coated
tubes; ii) addition of freshly labeled 125I-(TYR A19)-human insulin and iii) incubation for
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18–24 h at 4˚C. Rat insulin was provided by the above-mentioned kit. Human recombinant
free insulin was from Lilly. Both types of insulin were used to prepare standard curves. The
standard curves and problems were run in duplicate.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 5.0 software (GraphPad Software
Inc., La Jolla, Ca, USA). The results were expressed as the mean and standard error of the
mean (± SEM). Differences among groups were determined by ANOVA followed by Tukey0s
multiple comparison test. Normal distribution analysis before ANOVA analysis was per-
formed. The unpaired Student0s t test (two tailed) was also used. A.P< 0.05 was considered to
be significant. Figures were generated with GraphPad Prism 5.0.
Results
Effect of serum albumin on insulin radioimmunoassay
To evaluate the potential of RIA technique to discern the different antigenic forms of insulin,
Zn2+-insulin and Zn2+-free insulin were diluted in KRB buffer without BSA at the same
known concentration and incubated with I125 insulin in antibody-coated tubes. The results
were compared with standards prepared with the same commercial Zn2+-free insulin.
As shown in Fig 1.
3% BSA and 2 mmol/l Zn2+ had no effect on the RIA technique when added alone.
Although all insulin solutions had been prepared at the same concentration (250 pmol/l),
Zn2+-insulin reacted with the antibody to a much lesser degree than Zn2+-free insulin
Fig 1. T. Effect of serum albumin on insulin determination by radioimmunoassay. Insulin concentration was measured in different
KRB buffer solutions with 2 mmol/l ZnCl2 (Zn), 3% BSA (BSA), 250 mmol/l Zn2+-free insulin (insulin) and 250 mmol/l Zn2+-insulin (Zn-
insulin). Values are expressed as the mean ± SEM of 6 experiments. *P<0.01 compared with the other conditions.
https://doi.org/10.1371/journal.pone.0187547.g001
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(P<0.01). While the Zn2+-free-insulin concentration determined was close to the expected
concentration (262.9 ± 45.5 pmol/l), RIA failed to determine the accurate Zn2+-insulin com-
plex concentration (39.1 ± 19.6 pmol/l). However, no significant differences were found
between Zn2+ free insulin and Zn2+-insulin plus 3% BSA (262.9 ± 45.5 and 279.9 ± 60.8 pmol/l
respectively), most likely due to chelation of the Zn2+ by serum albumin and the subsequent
dissociation of Zn2+-insulin into Zn2+-free insulin. Thus, when 2 mmol/l ZnCl2 was added
into BSA-supplemented KRB buffer, the albumin-induced enhancement of insulin detection
was inhibited and the insulin determination was 5.1 ± 5.0 pmol/l, probably due to saturation
of the albumin Zn2+-binding sites.
Effect of serum albumin on insulin secreted in static incubations
Fig 2 shows effects of BSA and a Zn2+ chelator on insulin secreted in static incubation. When
batches of 3 islets were incubated without BSA, no significant differences were found between
the insulin detected after incubation of islets in 2.8 mmol/l glucose (35.9 ± 5.3 pg/islet/30 min)
and stimulation with 22.2 mmol/l glucose (50.1 ± 10.5 pg/islet/30 min) (Fig 2A). However, the
insulin detected in incubations with 3% BSA and 22.2 mmol/l glucose was 4.7-fold above that
seen with BSA and 2.8 mmol/l glucose (245.4 ± 22.8 and 51.7 ± 11.7 pg/islet/30 min respec-
tively, P<0.01). Similar differences were obtained in islets incubated with 1 mmol/l Zincon
when incubations at 22.2 and 2.8 mmol/l glucose were compared (212.4 ± 18.5 and 63.9 ± 16.4
pg/islet/30 min respectively, P<0.01), suggesting that BSA affects insulin detection by its
capacity to bind Zn2+.
To investigate if albumin was affecting insulin detection rather than insulin secretion, BSA
was added into KRB buffer after incubation, when islets had been removed, but before insulin
determination with RIA. The data are shown in Fig 2B. As in the case previously described
with BSA during the incubation, when BSA was added after islets were removed, the insulin
detected from experiments in 22.2 mmol/l glucose was 4-fold above that detected in 2.8
mmol/l glucose (214.3 15.4 and 52.4 10.8 respectively, P<0.01). Additionally, no significant
difference was found when comparing results obtained from islets incubated in 22.2 mmol/l
glucose plus BSA (Fig 2A) with those obtained with the same glucose concentration but with
BSA added into the buffer after incubation (Fig 2B) (245.4 ± 22.8 and 214.3 ± 15.4 pg/islet/30
min, respectively). Thus, serum albumin seems to affect insulin determination and not insulin
secretion mechanisms. On the other hand, two Zn2+ chelators mimicked the effect of BSA on
insulin determination. When Zincon was added into the effluent collected after incubation,
the insulin detected from experiments with 22.2 mmol/l glucose was approximately 3-fold
that detected from the control with 2.8 mmol/l (202.6 ± 53.3 and 71.0 ± 22.9 respectively,
#P<0.05). Additionally, Terpy showed similar effects (Fig 2B) (230.1 ± 30.9 and 71.6 ± 32.1
with 22 and 2.8 mmol/l glucose respectively, #P<0.05). These results suggest that Zn2+ chela-
tion by BSA facilitates Zn2+-insulin dissociation into monomers of Zn2+-free insulin after
secretion, consequently monomeric insulin is detected with the RIA technique when BSA is
absent; the predominant insulin form is Zn2+-insulin, which cannot be correctly determined
(Fig 1).
Effect of serum albumin on insulin-induced decrease in plasma glucose
levels and subcutaneous insulin absorption
It is established that Zn2+-insulin has different pharmacokinetic characteristics compared
with Zn2+-free insulin. In fact, insulin has frequently been mixed with an excess of Zn2+ to
obtain prolonged-action insulin preparations. To investigate the effects of serum albumin on
Zn2+-insulin-mediated changes in plasma glucose levels, ITT was performed in anesthetized
Albumin and Zn2+-insulin
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Fig 2. Effects of serum albumin and Zn2+ chelators on glucose-induced insulin secretion. Islets were
incubated with KRB buffer supplemented with 2.8 (-) or 22.2 mmol/l (+) glucose. (A) Incubations were carried
out with KRB buffer, in the absence of BSA and Zn2+ chelators (Con), plus 3% BSA (Alb) or 1 mmol/l Zincon
(Zin). (B) Islets were incubated in KRB buffer alone and 3% BSA (AlA), 1 mmol/l Zincon (ZiA) or 10 mmol/l
Terpy (TeA). Values are expressed as the mean ± SEM of 6 experiments. *P<0.01 compared with the other
conditions. #P<0.05 when ZiA+ and TeA+ were compared with ZiA- and TeA-, respectively.
https://doi.org/10.1371/journal.pone.0187547.g002
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rats using different solutions of insulin (Zn2+-free insulin, Zn2+-free insulin plus BSA, Zn2+-
insulin, Zn2+-insulin plus BSA and Zn2+-insulin plus 2 mmol/l ZnCl2 plus BSA) in KRB buffer.
All of the solutions were preincubated at 37˚C for 20 min before injection. The results are
shown in Fig 3.
In Fig 3A a significant decrease (P<0.01) in plasma glucose values was observed 20 min
after Zn2+ free insulins and Zn2+-insulin plus BSA injections compared with the rest of the
groups. A few minutes after injection of free insulin, a fall in plasma glucose levels was evident
(6.8 ± 0.4 vs. 3.5 ± 0.2 mmol/l glucose at 0 and 20 min respectively, P<0.01). Animals injected
with Zn2+-insulin showed non-significant differences between their basal plasma glucose level
measured at 0 min and that obtained at 20 min after injection (6.9 ± 0.4 and 4.8 ± 0.2 mmol/l
glucose, respectively) (Fig 3A). However, injection of Zn2+-insulin plus BSA solution had an
effect on plasma glucose levels similar to that of free insulin (7.0 ± 0.2 and 3.6 ± 0.1 mmol/l glu-
cose at 0 and 20 min respectively, P<0.01). Most likely, this decrease in plasma glucose levels
was caused by Zn2+-insulin dissociation into Zn2+-free insulin due to BSA. The effects of free
insulin and free insulin plus BSA on plasma glucose levels were also similar. Thus, as expected,
BSA had no effect on Zn2+-free insulin. When Zn2+-insulin plus Zn2+-BSA was injected, its
effects on plasma glucose levels were similar to those of Zn2+-insulin alone (6.0 ± 0.3 and
5.4 ± 0.4 mmol/l glucose at 0 and 20 min respectively). A very plausible explanation for this
result is that the Zn2+ ion inhibited the effect of BSA on insulin-induced decrease of plasma
glucose levels due to BSA Zn2+-binding site saturation.
Numerous lines of evidence provide strong support for the effects of hexamer aggrega-
tion on subcutaneous insulin absorption [22]. To determine whether BSA’s effect on insu-
lin-induced plasma glucose level changes was due to changes in insulin absorption kinetics,
serum insulin levels were measured after injection of the previously mentioned solutions
(Fig 3B). At 10 min after free insulin injection, serum insulin levels increased 32-fold com-
pared to basal (0.04 ± 0.05 and 1.4 ± 0.2 nmol/l insulin at 0 and 10 min after injection
respectively, P<0.01) reaching a plateau (Fig 3B). Similar results were obtained after injec-
tion of free insulin plus BSA (0.01 ± 0.01 and 1.8 ± 0.1 nmol/l insulin at 0 and 10 min after
injection, respectively, P<0.01) and Zn2+-insulin plus BSA (0.6 ± 0.4 and 1.5 ± 0.1 nmol/l
insulin at 0 and 10 min after injection respectively, P<0.01). Otherwise, rats treated with
Zn2+-insulin and Zn2+-insulin plus Zn2+-BSA solutions showed no significant increase
of serum insulin levels at 10 min compared to basal levels (Fig 3B). In addition, Zn2+ free
insulins and Zn2+-insulin plus BSA injections induced a significant increase (P<0.01) of
serum insulin levels compared with Zn2+-insulin and Zn2+-insulin plus Zn2+-BSA solutions.
All of these results were consistent with the previously described effects on plasma glucose
levels.
Effect of a Zn2+ chelator on K+-induced insulin secretion in perifused
islets of different sizes
In contrast with normal blood flow, in perifusion experiments the access of nutrients and
release of insulin from islets are governed by diffusion laws. The isolation process causes a dis-
ruption of islets’ vascular connections. Furthermore, pancreatic β-cells are densely packed at
the core of islets. Consequently, the insulin secreted into extracellular space from β-cells, in
isolated islets, must diffuse across the interstitial fluid to the islet surface before it is released to
the surrounding medium. Thus, it is expected that isolated islets will show a different pattern
of insulin release depending on the size of the islet. In this regard, insulin released from small
islets would arrive faster to the surface than that released from large islets. Furthermore, the
larger size of hexameric insulin probably lowers the diffusion rate through tissue. In fact,
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Fig 3. Effect of serum albumin on insulin pharmacokinetics. Rat plasma glucose levels (A) and serum
insulin levels (B) after injection of Zn2+-free insulin (Δ), Zn2+-free insulin plus 3% BSA (▲), Zn2+-insulin (),
Zn2+-insulin plus 3% BSA (●) and Zn2+-insulin plus 2 mmol/l ZnCl2 and 3% BSA (*). Values are expressed
as the mean ± SEM of 6 experiments for Fig 3A and 4 experiments for fig 3B. *P<0.01 compared with
Zn2+-insulin and Zn2+-insulin plus 2 mmol/l ZnCl2 and 3% BSA.
https://doi.org/10.1371/journal.pone.0187547.g003
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molecular size alters both the rate of diffusion through tissue as well as transport across the
capillary membrane [23].
The pattern of high K+-induced insulin secretion from large (308 ± 49 μm) and small
(56 ± 11 μm) islets is shown in Fig 4.
Perifused small-size islets responded to a stepwise increase in extracellular K+ with a clear-
biphasic rise of insulin secretion, consisting of a 4 min transient burst followed by a plateau
that lasted as long as the high K+ stimulus (Fig 4A). However, in perifused large-size islets,
high K+ levels induced the same rapid increase of insulin release followed by a slow and steady
fall in the insulin secreted (Fig 4A). If diffusion depends on hexamer size compared to mono-
mer, a Zn2+ chelator will accelerate the rate. This is shown in Fig 4B. When zincon was added
to the perifusion medium, the dynamics of high K+-induced insulin release from both large
and small islets followed a similar well-marked biphasic pattern (Fig 4B). Zincon modified the
pattern of high K+-induced insulin secretion from large islets, but no significant effect was
found on the dynamics of insulin release from small islets (Fig 4B) compared with islets peri-
fused without the Zn2+ chelator (Fig 4A).
Discussion
Serum albumin alters insulin measurements but not insulin release
As shown in Fig 1, while Zn2+-free insulin concentrations were determined with significant
accuracy using an immunological assay, we failed to correctly determine Zn2+-insulin concen-
tration in the absence of a Zn2+ chelator. This finding demonstrated that insulin immunoassay
techniques efficiently recognize insulin monomer but not Zn2+-insulin polymer. Provided that
an important part of the monomer of insulin is located at the hexamer-forming surface of the
molecule [24], a highly significant fraction of the polyclonal antibodies against monomeric
insulin used in the insulin immunoassay techniques are most likely incapable of recognizing
the antigenic form of hexameric Zn2+-insulin. In agreement with this hypothesis, it has been
suggested that Zn2+-insulin and Zn2+-free insulin are different antigenic forms and this can
alter the insulin concentrations determined with immunological assays [25,26]. On the other
hand, Fig 1 shows that when serum albumin is added, Zn2+-insulin can be determined at its
actual concentration. Previous works have shown that serum albumin has a strong binding
site for Zn2+ [15]. Furthermore, it is well established that at pH 7.3, Zn2+ ion is essential to con-
taining the repulsion of the carboxylic acids of the six GluB13 residues packed closely together
at the center of the insulin hexamer. When Zn2+ disappears, the strong mutual repulsion of
these residues can cause the hexamer to disintegrate into monomers [11]. Thus, it is likely that
albumin competes with insulin for Zn2+ and facilitates Zn2+-insulin disintegration into mono-
meric Zn2+-free insulin, thereby releasing the antigens hidden in the hexameric structure and
allowing antibodies against monomeric insulin to bind with the monomers. As a matter of
fact, when albumin’s Zn2+ binding site was saturated with a high Zn2+ concentration, albumin
did not improve the Zn2+-insulin determination as expected if albumin’s effect was mediated
by its Zn2+ binding properties (Fig 1). In contrast with their clear effects on Zn2+-insulin hex-
amers, albumin and Zn2+ chelators do not modify insulin release and proper glucose-induced
insulin release is observed (Fig 2). Any direct effect of albumin or Zn2+ chelators on the insulin
secretory machinery may be negligible since the absence of both albumin and Zn2+ chelators
during the secretion process does not affect the measured insulin provided they are present
during the immunological assay (Fig 2).
The most plausible hypothesis is that serum albumin chelates Zn2+ from Zn2+-insulin hex-
amer reversibly dissociating it into insulin monomer (Fig 5).
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Fig 4. Effect of Zn2+ chelator on insulin secretion pattern. (A) Large (●) and small () islets were perifused with KRB
buffer plus 0.1% BSA and 2.8 mmol/l glucose plus 50 mmol/l K+ as indicated by the bars. (B) Large (▲) and small (Δ)
islets were perifused as previously mentioned but 1 mmol/l Zincon was added to the solution. Values are expressed as
the mean ± SEM of 4 experiments. Data have been normalized to minimum and maximum values to compare insulin
secretory patterns. *P<0.01 compared with small islets between minutes 7 and 15.
https://doi.org/10.1371/journal.pone.0187547.g004
Albumin and Zn2+-insulin
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Serum albumin may alter Zn2+-insulin’s pharmacokinetic characteristics
The ratio of serum insulin level increase after subcutaneous administration depends on insulin
absorption from the tissue. Several different variables are implicated in the absorption rate of
subcutaneously injected insulin, such as subcutaneous fat thickness, skin temperature [27]
and, especially, insulin characteristics [9,28]. Thus, capillary diffusion capacity depends on the
size of the insulin molecule. Insulin monomer (approximately 6000 kD) is absorbed rapidly,
and the larger Zn2+-insulin hexamer (approximately 36000 kD) is absorbed at much lower
rates [22]. Subsequently, plasma glucose levels decreased faster after subcutaneous injection of
Zn2+-free insulin than after Zn2+-insulin administration (Fig 3A). At the same time, faster
increases in blood insulin levels were achieved with Zn2+-free insulin (Fig 3B). These results
can be explained by differences in the absorption ratio of each insulin form. Conversely, pre-
incubation with serum albumin altered Zn2+-insulin’s pharmacokinetics, and under this
Fig 5. Serum albumin dissociates hexameric Zn2+-insulin into active monomers. Serum albumin chelates Zn2+. In turn, the Zn2+ free
concentration decreases. Thus, serum albumin improves hexameric Zn2+-insulin dissociation into active Zn2+-free insulin monomer.
https://doi.org/10.1371/journal.pone.0187547.g005
Albumin and Zn2+-insulin
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condition, Zn2+-insulin mimics the effects on plasma glucose levels and serum insulin levels
obtained with Zn2+-free insulin. Furthermore, Zn2+-free insulin’s action was unaffected by
previous incubation with albumin, and the effect of serum albumin on Zn2+-insulin pharma-
cokinetics was abrogated by addition of Zn2+ (Fig 3). All these data strongly support the notion
that serum albumin increases the ratio of Zn2+-insulin absorption, improving the dissociation
of hexamers into lower-molecular-weight subunits. Thus, serum albumin alters the character-
istics of insulin, transforming long-action Zn2+-insulin into short-action insulin.
Zn2+ buffering affects Zn2+-insulin diffusion through interstitial fluid after
secretion
Insulin hexamers diffuse through the interstitial fluid of the extracellular space at approxi-
mately half the rate of insulin monomers [9]. Consequently, hexamers may be arriving at the
surface of islets more slowly than the monomer form. The presence of a Zn2+ chelator acceler-
ated the intercellular conversion of hexamers into monomers, and then the difference in the
pattern between large and small islets disappeared (Fig 4B). Most likely, the low-molecular-
weight Zn2+-chelator diffuses into the islets and improves hexamer dissociation into lower
molecular size subunits, which diffuse quickly. Consequently, the pattern of insulin release was
less affected by the size of the islets. These results support the hypothesis that insulin is secreted
as a hexamer and requires a Zn2+ chelator to dissociate into subunits. In addition, the data sug-
gest that the islet vascular network may be relevant to ensuring albumin availability in the core
of the islets and fast conversion of Zn2+-insulin into the easily diffusible monomer after exocy-
tosis. In addition, the studies [29,30] indicates that oxygen tension and islet size are important
factors that affect insulin release in isolated islets.
Technical and methodological considerations
This study has demonstrated that albumin or a Zn2+ chelator improves Zn2+-insulin disinte-
gration into subunits, which could affect insulin detection by immunological assays. Thus,
insulin determination in in vitro insulin-release experiments is clearly sensitive to the presence
of serum albumin in the solution since insulin seems to be released as a hexamer [5,11]. These
findings may raise doubts regarding the correct interpretation of the results of several studies,
in which some authors evaluate the potential of different techniques to discern hexameric
insulin from the monomer form, using albumin in their protocols [25,31]. On the other hand,
Zn2+ inhibition of insulin [20,32] and glucagon release [33] have been reported. In these stud-
ies, the addition of Zn2+ into the solution may be saturating albumin’s Zn2+ binding sites.
Thus, Zn2+-insulin does not dissociate into subunits and could affect insulin-induced insulin
release [10] and insulin’s effects on glucagon release [33]. The authors suggest that Zn2+ has a
direct effect on secretion; however an indirect effect on Zn2+-insulin dissociation cannot be
ruled out. Other experiments can also be affected by serum albumin. The results from experi-
ments testing the effects of drugs and nutrients on insulin release may be altered by the pres-
ence of albumin in the medium, since albumin binds to them [34] and reduces the active free
concentration of the specific tested compound. Additionally, commercial albumin can be
bound to nutrients, ions or other serum substances, and this could affect the results of some
specific experiments. For these and other reasons albumin could affect the correct interpreta-
tion of data. Thus, replacement of albumin with Zn2+ might seem warranted in order to avoid
those problems.
Pancreatic islets are densely vascularized micro-organs. Islet processing for clinical trans-
plantation disconnects these structures from the vascular tree, disrupts the access to oxygen
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and nutrients [35] and delays insulin diffusion to the surface. While this may be secondary for
small islets, it could affect the regulatory role of diffusion.
Our data suggest that Zn2+ insulin may not be properly dissociated in the absence of albu-
min, which could lead to suboptimal function of the islets after transplantation.
In conclusion, although it has been proposed that under physiological conditions changes
in pH, clearance of insulin concentration and Zn2+ dilution result in hexameric insulin disso-
ciation into subunits [5,11], these results indicate that the primary factor in this process is the
chelation of Zn2+ by serum albumin. Several considerations agree with this hypothesis. It has
been shown that Zn2+ concentrations (5 μmol/l) lower than those found in serum (approxi-
mately 15–25 μmol/l) could reduce hexameric insulin dissociation into monomer [5]. In
addition, the dissociation of Zn2+-insulin just after exocytosis may be regulated by albumin
concentrations in the extracellular space. It has been reported that the albumin concentration
in the interstitial fluid of islets increases in diabetic patients [17]. However, whether changes in
local concentrations of albumin affect the autocrine and paracrine functions of insulin in the
islet remains to be explored.
Furthermore, islets are structures profusely irrigated. They represent 1% of the total mass of
the pancreas and receive 20% of the blood flow. Islets’ β-cells are close to the fenestrated endo-
thelium (Fig 5), building a functional unit that is lost in islet transplantation procedures
[36,37]. In other organs, such as the lung, free Zn2+ induces endothelial cell contraction [38], a
process that is augmented by nitric oxide [39,40]. This mechanism might also operate in pan-
creatic islets in hypoxic conditions in a process dependent on the generation of high levels of
nitric oxide [41,42]. Whether or not this observation is mimicked by human islet endothelium
under inflammatory conditions needs further exploration. Moreover, in larger human, islets
insulin- Zn2+ hexamers will take longer to reach the systemic blood flow. This diffusion delay
will slow the corresponding regulatory feedback between peripheral tissue glucose uptake and
the subsequent decrease in glucose-induced insulin release. Our observations open new venues
in integrative islet physiology, pathophysiology and transplantation.
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